

1 Performance of Screening for SARS-CoV-2 using Rapid Antigen Tests to Detect Incidence of
2 Symptomatic and Asymptomatic SARS-CoV-2 Infection: findings from the Test Us at Home
3 prospective cohort study

4 Apurv Soni MD, PhD^{1,2,3}, Carly Herbert BA¹, Honghuang Lin PhD^{1,3}, Caitlin Pretz MS¹, Pamela
5 Stamegna MD¹, Taylor Orwig BS¹, Colton Wright MS¹, Seanan Tarrant BS¹, Stephanie Behar
6 BA¹, Thejas Suvarna BBA, BS⁴, Summer Schrader BA⁴, Emma Harman MPH⁴, Chris Nowak
7 BA⁴, Vik Kheterpal MD⁴, Lokinendi V Rao PhD⁵, Lisa Cashman MPH⁵, Elizabeth Orvek MS²,
8 Didem Ayturk MS², Peter Lazar BS², Ziyue Wang MPH⁶, Bruce Barton PhD², Chad J.
9 Achenbach MD, MPH⁷, Robert L. Murphy MD⁷, Matthew Robinson MD⁸, Yuka Manabe MD⁸,
10 Biqi Wang PhD^{1,3}, Shishir Pandey BE¹, Andres Colubri PhD⁹, Laurel O'Connor MD¹⁰, Stephenie
11 C. Lemon PhD², Nisha Fahey DO, ScM^{1,2,11}, Katherine L Luzuriaga MD^{12,13}, Nathaniel Hafer
12 PhD¹², William Heetderks PhD¹⁴, John Broach MD, MPH, MBA¹⁰, David D McManus MD,
13 ScM^{1,2,6}

14 Affiliations:

15 ¹Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan
16 Medical School, Worcester, MA, USA

17 ²Department of Population and Quantitative Health Sciences, University of Massachusetts Chan
18 Medical School, Worcester, MA, USA

19 ³Division of Clinical Informatics, Department of Medicine, University of Massachusetts Chan
20 Medical School, Worcester, MA, USA

21 ⁴CareEvolution, LLC, Ann Arbor, MI, USA

22 ⁵Quest Diagnostics, Marlborough, MA, USA

23 ⁶Division of Cardiology, Department of Medicine, University of Massachusetts Chan Medical
24 School, Worcester, MA, USA

25 ⁷Division of Infectious Disease, Department of Medicine, Havey Institute for Global Health,
26 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

27 ⁸Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of
28 Medicine, Baltimore, MD, USA

29 ⁹Department of Microbiology and Physiological Systems, University of Massachusetts Chan
30 Medical School, Worcester, MA, USA

31 ¹⁰Department of Emergency Medicine, University of Massachusetts Chan Medical School,
32 Worcester, MA, USA

33 ¹¹Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, MA,
34 USA

35 ¹²University of Massachusetts Center for Clinical and Translational Science, University of
36 Massachusetts Chan Medical School, Worcester, MA, USA

37 ¹³Program in Molecular Medicine, University of Massachusetts Chan Medical School,
38 Worcester, MA, USA

39 ¹⁴National Institute of Biomedical Imaging and Bioengineering, NIH, via contract with Kelly
40 Services, Bethesda, MD, USA

41 Corresponding Author:
42 Apurv Soni, MD PhD
43 Assistant Professor, Program in Digital Medicine
44 Department of Medicine
45 UMass Chan Medical School
46 Worcester, MA
47 01605
48
49

50 **Abstract**

51 **Background:** Performance of Rapid Antigen Tests for SARS-CoV-2 (Ag-RDT) varies over the
52 course of an infection, and their performance is not well established among asymptomatic
53 individuals.

54 **Objective:** Evaluate performance of Ag-RDT for detection of SARS-CoV-2 in relation to onset of
55 infection for symptomatic and asymptomatic participants.

56 **Design, Setting, and Participants:** Prospective cohort study conducted from October 2021 to
57 February 2022 among participants > 2 years-old from across the US who enrolled using a
58 smartphone app. During each testing encounter, participants self-collected one nasal swab and
59 performed Ag-RDT at home; at-least fifteen minutes later, a second nasal swab was self-
60 collected and shipped for SARS-CoV-2 RT-PCR at a central lab. Both nasal swabs were
61 collected 7 times at 48-hour intervals (over approximately 14 days) followed by an extra nasal
62 swab collection with home Ag-RDT test 48-hours after their last PCR sample. Each participant
63 was assigned to one of the three emergency use authorized (EUA) Ag-RDT tests used in this
64 study. This analysis was limited to participants who were asymptomatic and tested negative by
65 antigen and molecular test on their first day of study participation.

66 **Exposure:** SARS-CoV-2 positivity was determined by testing a single home-collected anterior
67 nasal sample with three FDA EUA molecular tests, where 2 out of 3 positive test results were
68 needed to determine a SARS-CoV-2 positive result. Onset of infection was defined as day on
69 which the molecular PCR comparator result was positive for the first time.

70 **Main Outcomes and Measures:** Sensitivity of Ag-RDT was measured based on testing once
71 (same-day), twice (at 48-hours) and thrice (at 96 hours). Analysis was repeated for different
72 Days Post Index PCR Positivity (DPIPP) and stratified based on symptom-status on a given
73 DPIPP.

74 **Results:** A total of 7,361 participants enrolled in the study and 5,609 were eligible for this
75 analysis. Among 154 eligible participants who tested positive for SARS-CoV-2 infection based
76 on RT-PCR, 97 were asymptomatic and 57 had symptoms at onset of infection (DPIPP 0).
77 Serial testing with Ag-RDT twice over 48-hours resulted in an aggregated sensitivity of 93.4%
78 (95% CI: 89.1-96.1%) among symptomatic participants on DPIPP 0-6. Among the 97 people
79 who were asymptomatic at the onset of infection, 19 were singleton RT-PCR positive, i.e., their
80 positive test was preceded and followed by a negative RT-PCR test within 48-hours. Excluding
81 these singleton positives, aggregated sensitivity on DPIPP 0-6 for two-time serial-testing among
82 asymptomatic participants was lower 62.7% (54.7-70.0%) but improved to 79.0% (71.0-85.3%)
83 with serial testing three times at 48-hour interval.

84 **Discussion:** Performance of Ag-RDT within first week of infection was optimized when
85 asymptomatic participants tested three-times at 48-hour intervals and when symptomatic
86 participants tested two-times separated by 48-hours.

87

88

89

90

91 **Key points**

92 **Question:**

93 What is the performance of serial rapid antigen testing (Ag-RDT) in the first week of infection
94 among symptomatic and asymptomatic SARS-CoV-2 infections?

95 **Findings:**

96 Serial testing with Ag-RDT two-times separated by 48-hours resulted in detection of more than
97 90% of SARS-CoV-2 infections when symptomatic participants began testing within first week
98 from onset of molecular positivity; participants who were asymptomatic when they began testing
99 within the first-week of molecular positivity observed a sensitivity of 79.0% when they performed
100 three rapid antigen-tests, 48 hours apart.

101 **Meaning:**

102 To optimize detection of SARS-CoV-2 infection with home antigen tests, people suspected to be
103 infected with SARS-CoV-2 virus should test twice at least 48-hours apart if they are
104 symptomatic and three times at 48-hour intervals if they do not have symptoms (asymptomatic).

105

106

107

108 **Key definitions:**

109 Comparator positive: composite definition of molecular positivity if majority of molecular assays
110 were positive

111 Days Past Index Comparator Positive (DPIPP): Number of calendar-days past the day when
112 first Comparator positive was observed

113 Onset of Infection: DPIPP 0, when first Comparator positive was observed

114 Symptomatic and Asymptomatic Cases: Based on presence or absence of self-reported
115 symptoms on the day of testing. Sensitivity was measured for Symptomatic and Asymptomatic
116 cases on DPIPP 0-10

117 First week of Infection: DPIPP 0 - 6

118

119

120

121

122

123

124

125 **Introduction**

126 SARS-CoV-2 diagnostic testing remains a cornerstone in our nation's fight against COVID-19,
127 and at-home rapid antigen tests (Ag-RDTs), while not perfect, provide a fast and convenient
128 testing option. This type of test is available without a prescription (i.e., over-the-counter [OTC]),
129 easy-to-use, widely available, and, in some cases, preferred by the population over molecular
130 assays that require appointments, waiting in-line at testing centers, and waiting 24-48 hours for
131 results.¹⁻³ Despite their popularity, key gaps remain in our understanding of these tests, notably
132 their performance among asymptomatic people. Reports on Ag-RDT performance among
133 asymptomatic individuals have been highly varied, ranging from sensitivities of 35.8% to 71% in
134 cross-sectional screening evaluations.^{4,5} However, few studies have evaluated serial testing
135 performance of Ag-RDTs among asymptomatic individuals. Furthermore, emergency use
136 authorization (EUA) holders of OTC antigen tests are responsible for demonstrating Ag-RDT
137 performance in a population with asymptomatic infection using serial testing. This manuscript
138 describes primary findings from a large study designed in coordination with the National
139 Institutes of Health (NIH), Food and Drug Administration (FDA), and three major rapid antigen
140 test manufacturers to evaluate the performance of serial testing using rapid antigen tests for
141 detection of SARS-CoV-2 among asymptomatic individuals within the first week of infection.

142 **Methods**

143 *Study Population and Design:* This prospective cohort study enrolled participants between
144 October 18, 2021 and January 31, 2022 over the age of two years from across the country
145 through a novel digital siteless study protocol. Details of the study design and protocol are
146 described elsewhere.⁶ This study was approved by WIRB-Copernicus Group (WCG) Institutional
147 Review Board (20214875). In brief, participants were eligible to enroll through a smartphone
148 app if they did not have a SARS-CoV-2 infection in the prior three months, were without any
149 symptoms in the 14 days prior to enrollment and were able to drop-off prepaid envelopes with

150 nasal swab samples at their local FedEx drop-off location. Enrolled participants were assigned
151 to one of three types of EUA Ag-RDT (Quidel QuickVue At-Home OTC COVID-19 Test,
152 BinaxNow COVID-19 Antigen Self-Test, or BD Veritor At-Home COVID-19 Test) and received a
153 home delivery of 10 Ag-RDTs and 7 home collection kits for reverse transcriptase polymerase
154 chain reaction (RT-PCR) samples. Participants were asked to perform two self-collected
155 bilateral anterior nasal swab collections and paired testing (Ag-RDT (at home) and RT-PCR
156 (mailed to central lab)) every 48-hours for 7 times over a two-week period, with an additional
157 end of study bilateral anterior nasal swab collection with home Ag-RDT test 48-hours after the
158 last paired test. Two FDA-authorized, high sensitivity RT-PCR assays were performed on each
159 nasal swab sample received at the central lab, and an additional tiebreaker assay was
160 performed if the two RT-PCR assays were discordant.

161 *Measures:* Ag-RDT results were based on self-report (Quidel QuickVue At-Home OTC COVID-
162 19 Test, BinaxNow COVID-19 Antigen Self-Test) or automatic reader (BD Veritor At-Home
163 COVID-19 Test), as per EUA instructions for use. Molecular comparator RT-PCR results were
164 based on a combination of molecular test results for detection SARS-Cov-2 infection
165 (Supplementary Table 1), and onset of infection was defined as day on which the molecular
166 comparator result was positive for the first time. To approximate performance of Ag-RDT if a
167 person starts testing on different from onset of infection, we identified Days Past Index PCR
168 Positivity (DPIPP) as different strata, for which, performance was calculated. Symptomatic or
169 asymptomatic classification was based on presence or absence of symptoms on DPIPP for
170 which the performance is calculated. Therefore, an individual who was asymptomatic on DPIPP
171 0 may become symptomatic on DPIPP 2 and vice-versa.

172 *Statistical Analysis:* Participants were eligible for inclusion in this analysis if they did not report
173 any symptoms on the first day they started testing and they had a negative SARS-CoV-2
174 molecular and Ag-RDT tests. Our decision to pool performance across the different tests was

175 also based on 1) findings not shown in this report that suggested the sensitivity of different Ag-
176 RDT was similar to each other as a function of the viral load and 2) The study was not designed
177 to evaluate differences in performance between the three different types of Ag-RDTs.
178 Performance was calculated using sensitivity (rapid antigen positivity/comparator positivity) for
179 single-day testing, two-times serial testing, and three-times serial testing for symptomatic and
180 asymptomatic individuals based on day and patterns of positivity, as described in Table 1.
181 Calculations for sensitivity were repeated with testing starting on different DPIPP. Current 95%
182 confidence intervals are calculated using Clopper-Pearson method for binomial probability. To
183 account for repeated measures within participants, we will update this preprint with confidence
184 intervals estimated using bootstrapping technique.⁷ Negative Percent Agreement was calculated
185 as a proportion of paired tests (Ag-RDT and molecular tests performed on the same-day) based
186 on the following formula: True-Negative/[False-Positive+True-Negative] where True-Negative
187 refers to instances a negative molecular test was paired with a negative Ag-RDT on the same
188 day and False-Positive refers to a negative molecular test paired with a positive Ag-RDT test. All
189 analyses were performed using R 4.1.1.⁸

190 **Results**

191 A total of 7,361 participants enrolled in the study, and 5,609 were eligible for this analysis. Of
192 these, 154 individuals tested RT-PCR positive for SARS-CoV-2 during the study based on a
193 composite definition described in Supplementary Table 1; 97 were without symptoms and 57
194 had symptoms at infection onset. Among the 5,455 participants who did not test positive, there
195 were 39,682 days of paired Ag-RDT and RT-PCR testing, where comparator result was
196 negative. Among these, 39,503 days had a concordant Ag-RDT negative result, yielding a
197 negative percent agreement of 99.5% (95% CI: 99.5-99.6%).

198 Performance of Ag-RDT to detect SARS-CoV-2 on day of infection onset (DPIPP: 0) was higher
199 among symptomatic participants (59.6%, 46.7-71.4%) in comparison to asymptomatic

200 participants (9.3%, 5.0-16.7%) (Figure 2; Supplementary Table 2). Serial-testing with two Ag-
201 RDT tests 48-hours apart (Symptomatic: 92.2%, 81.5-96.9%; Asymptomatic: 39.3%, 29.8-
202 49.7%) and three Ag-RDT tests 48-hours apart (Symptomatic: 93.6%, 82.8-97.8%;
203 Asymptomatic: 56.4%, 45.4-66.9%) improved performance of Ag-RDT. Notably, we observed
204 that twenty participants had a singleton RT-PCR+, defined as a positive test preceded and
205 followed by a negative RT-PCR test within 48-hours. Of those with singleton RT-PCR+ tests,
206 none tested positive on Ag-RDT and only one had symptoms on the day of the singleton
207 positive test. Excluding these participants did not impact sensitivity of Ag-RDT among
208 symptomatic participants, but improved asymptomatic sensitivity to 11.7%, 50.7%, and 74.6%
209 based on testing one, two, or three times with Ag-RDT at 48-hour intervals, respectively, on
210 DPIP 0.

211 To approximate real-world scenarios, where a person may not necessarily start testing with Ag-
212 RDT on the day of infection onset, we calculated performance separately on DPIP 2, 4, 6, 8,
213 and 10 (Figure 2; Supplementary Table 2) to approximate scenarios where a person started
214 serially testing with Ag-RDTs on those days. Aggregated performance of Ag-RDT for DPIP 0-6
215 among those who were symptomatic on a given DPIP was 82.5% (76.8-87.0%) for single-
216 timepoint testing but with a range of sensitivity from 59.6 to 94.8%. Serial-testing using two-time
217 testing improved sensitivity to 93.4% (89.0-96.5%) and 94.3% (89.4-97.3%) for three-time
218 testing. Sensitivity of performing single test, two-test serial testing, and three-test serial testing
219 for asymptomatic people was 34.2% (27.4-41.7%), 55.6% (47.8-63.1%), 68.8% (60.5-76.2%),
220 respectively during the first week of infection (DPIP 0-6). Excluding singleton RT-PCR positive,
221 the first-week (DPIP 0-6) sensitivity was 38.5% (31.0-46.5%), 62.9% (54.7-70.6%), 79.2%
222 (71.0-85.9%), respectively for testing one, two, or three times with Ag-RDT at 48-hour intervals.

223 Discussion

224 These findings from the largest study to date use paired Ag-RDT and RT-PCR testing for a
225 comparative performance evaluation of Ag-RDTs among people with and without symptoms.
226 These results provide compelling reasons to suggest that Ag-RDT occurrences and timeframes
227 should be increased relative to the existing indications for use. These data suggest an
228 improvement in test performance when symptomatic individuals test two times 48-hours apart
229 using Ag-RDTs. Likewise, there are notable performance improvements in asymptomatic
230 individuals when a single Ag-RDT test was followed by at least 2 subsequent tests at 48-hour
231 intervals. Additionally, the rates of false positive results in the study were low; therefore, any Ag-
232 RDT positive result should be considered positive without the need to retest. These results
233 should be considered in the context of our study protocol which indicated testing at 48-hour
234 intervals, and thus these data cannot support conclusions about serial testing for time intervals
235 shorter than 48-hours.

236 These findings represent a comprehensive evaluation of the time dependent performance of Ag-
237 RDT tests by studying the intended use population (i.e., symptomatic and asymptomatic
238 individuals) throughout the course of molecular test positivity. Unlike previous reports, which
239 used composite sampling methods and did not have sufficient longitudinal data to adequately
240 evaluate performance of Ag-RDT from the onset of infection, we were able to approximate
241 performance of Ag-RDT for symptomatic and asymptomatic users by comparing performance
242 within the first week of infection to align with the indications listed in the EUA.^{9,10} The finding of
243 singleton RT-PCR positive testing needs to be further investigated to understand the clinical
244 significance of this observation.

245 Public health implications of our findings suggest that people who are suspected to be infected
246 with SARS-CoV-2 should exercise caution despite an initial negative rapid antigen-test and
247 favor mask-wearing and avoiding crowded places. In context of reports of viral culture positivity
248 more than five days after initial positive test, our findings support isolation for a longer period of

249 time to prevent the potential of spread of SARS-CoV-2 to others.¹¹ Further research is needed
250 to quantitatively estimate the benefits of Ag-RDT for early detection of infection and initiation of
251 treatment, especially in settings where access to molecular testing is limited or molecular test
252 results are delayed. Dissemination of clear guidance for appropriate testing using Ag-RDT
253 based on data from this study may help preserve confidence in the performance of serial Ag-
254 RDT to detect SARS-CoV-2 virus, especially as reports of individual false negative Ag-RDT
255 from inadequate serial testing, contrary to the tests' intended usage and guidance from the
256 FDA, proliferate in lay media.

257

258 Competing Interest Statement: DDM reports consulting and research grants from Bristol-Myers
259 Squibb and Pfizer, consulting and research support from Fitbit, consulting and research support
260 from Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial
261 research support from Apple Computer, consulting/other support from Heart Rhythm Society.
262 YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-
263 related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives
264 funding support to Johns Hopkins University from miDiagnostics.

265 Funding Statement: This study was funded by the NIH RADx Tech program under
266 3U54HL143541-02S2 and NIH CTSA grant UL1TR001453. The views expressed in this
267 manuscript are those of the authors and do not necessarily represent the views of the National
268 Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood
269 Institute; the National Institutes of Health, or the U.S. Department of Health and Human
270 Services. Salary support from the National Institutes of Health U54HL143541, R01HL141434,
271 R01HL137794, R61HL158541, R01HL137734, U01HL146382 (AS, DDM), U54EB007958-13
272 (YCM, MLR), AI272201400007C, UM1AI068613 (YCM), U54EB027049 and U54EB027049-
273 02S1 (CJA, RLM).


274 Acknowledgment: We are grateful to our study participants and to our collaborators from the
275 National Institute of Health (NIBIB and NHLBI) who provided scientific input into the design of
276 this study and interpretation of our results, but could not formally join as co-authors due to
277 institutional policies and to the Food and Drug Administration (Office of In Vitro Diagnostics and
278 Radiological Health) for their involvement in the primary TUAH study. We received meaningful
279 contributions from Drs. Bruce Tromberg, Jill Heemskerk, Dennis Buxton, Erin Iturriaga, Jue
280 Chen, Andrew Weitz, and Krishna Juluru. We are thankful to county health departments across
281 the country who helped with recruitment for this siteless study by spreading the word in their
282 networks.

283 References

- 284 1. Ricks S, Kendall EA, Dowdy DW, Sacks JA, Schumacher SG, Arinaminpathy N. Quantifying the
285 potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis.
286 *BMC Medicine*. 2021;19(1):75. doi:10.1186/s12916-021-01948-z
- 287 2. Møller IJB, Utke AR, Rysgaard UK, Østergaard LJ, Jespersen S. Diagnostic performance, user
288 acceptability, and safety of unsupervised SARS-CoV-2 rapid antigen-detecting tests performed at
289 home. *International Journal of Infectious Diseases*. 2022;116:358-364.
290 doi:10.1016/j.ijid.2022.01.019
- 291 3. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises
292 and challenges. *The Lancet Infectious Diseases*. 2021;21(9):e290-e295. doi:10.1016/S1473-
293 3099(21)00048-7
- 294 4. Siddiqui ZK, Mihir C, Robinson ML, et al. Implementation and Accuracy of BinaxNOW Rapid
295 Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-
296 Referred Testing Site. *Microbiology Spectrum*. 2021;9(3):e01008-21.
297 doi:10.1128/Spectrum.01008-21
- 298 5. Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW Rapid Antigen
299 Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona,
300 November 3–17, 2020. *Morbidity and Mortality Weekly Report*. 2021;70(3):100.
301 doi:10.15585/MMWR.MM7003E3
- 302 6. Soni A, Herbert C, Pretz C, Stamegna P, Filippaios A. Finding a Needle in the Haystack: Design and
303 Implementation of a Digital Site-less Clinical Study of Serial Rapid Antigen Testing to Identify
304 Asymptomatic SARS-CoV-2 Infection. *medRxiv*. Published online August 8, 2022.
- 305 7. Davison AC, Hinkley D v. *Bootstrap Methods and Their Application*. Cambridge University Press;
306 1997. doi:DOI: 10.1017/CBO9780511802843
- 307 8. R Development Core Team. R: A language and environment for statistical computing. Published
308 online 2022.
- 309 9. Winnett AV, Akana R, Shelby N, et al. Extreme differences in SARS-CoV-2 Omicron viral loads
310 among specimen types drives poor performance of nasal rapid antigen tests for detecting
311 presumably pre-infectious and infectious individuals, predicting improved performance of
312 combination specimen antigen tests. *medRxiv*. Published online January 1,
313 2022:2022.07.13.22277513. doi:10.1101/2022.07.13.22277513
- 314 10. Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-PCR
315 and Viral Culture During the Course of SARS-CoV-2 Infection. *JAMA Internal Medicine*.
316 2022;182(7):701-709. doi:10.1001/jamainternmed.2022.1827
- 317 11. Boucau J, Marino C, Regan J, et al. Duration of Shedding of Culturable Virus in SARS-CoV-2
318 Omicron (BA.1) Infection. *New England Journal of Medicine*. 2022;387(3):275-277.
319 doi:10.1056/NEJMc2202092

320

Figure 1: CONSORT Diagram for Test Us At Home Study to Calculate Performance of Rapid Antigen Tests for Detection of SARS-CoV-2 Virus




a= participants replaced their assigned rapid antigen tests with commercially obtained rapid antigen tests; b= dates of RT-PCR testing could not be verified based on triangulation of self-reported, shipping, and resulting data

Table 1: Matrix for Calculation of Sensitivity of Rapid Antigen Tests for Detection of SARS-CoV-2 Virus in Relation to Days Past Index PCR Positivity (DPIPP)

| Days Past Index PCR Positivity – DPIPP (strata) | Denominator for Sensitivity: PCR Positive on following DPIPP | Numerator for Sensitivity: At least one positive rapid antigen test on one of the following DPIPP (the other days could not be missing, invalid, or uninterpreted) | | |
|---|--|--|-----------------------|-----------------------|
| | | Single test | 2-test serial testing | 3-test serial testing |
| 0 | 0 | 0 | 0, 2 | 0, 2, 4 |
| 2 | 0 and 2 | 2 | 2, 4 | 2, 4, 6 |
| 4 | 0 and 4 | 4 | 4, 6 | 4, 6, 8 |
| 6 | 0 and 6 | 6 | 6, 8 | 6, 8, 10 |
| 8 | 0 and 8 | 8 | 8, 10 | 8, 10, 12 |
| 10 | 0 and 10 | 10 | 10, 12 | NA |

Classification of symptomatic vs asymptomatic based on symptom self-report on DPIPP

Figure 2: Performance of Rapid Antigen Tests for Detection of SARS-CoV-2 Virus in Relation to First Day of Molecular Positivity



Supplementary Table 1: Definition of Positive Comparator Test Based on Molecular Assays

| Roche cobas SARS-CoV-2 Test | Quest SARS-CoV-2 RT-PCR | Hologic Aptima SARS-CoV-2 Assay | Comparator |
|------------------------------------|--------------------------------|--|-------------------|
| DETECTED | DETECTED | Other | Positive |
| DETECTED | Other | DETECTED | Positive |
| Other | DETECTED | DETECTED | Positive |
| DETECTED | DETECTED | DETECTED | Positive |

Other: NOT DETECTED, INVALID, or ASSAY NOT PERFORMED
If Roche and Quest LDT were discordant and Aptima result was missing or not performed due to insufficient sample, that data point was excluded from the analysis

Supplementary Table 2: Sensitivity of Rapid Antigen Tests (Ag-RDT) based on symptom status on different Days Past Index PCR Positivity (DPIPP)

| Time | Symptomatic (All participants) | | | Asymptomatic (All participants) | | | Symptomatic (Excludes Singleton PCR+) | | | Asymptomatic (Excludes Singleton PCR+) | | |
|------------|-----------------------------------|--------------------------------|--------------------------------|------------------------------------|-------------------------------|-------------------------------|--|--------------------------------|--------------------------------|---|-------------------------------|-------------------------------|
| | 1x test | 2x test | 3x test | 1x test | 2x test | 3x test | 1x test | 2x test | 3x test | 1x test | 2x test | 3x test |
| DPIPP 0 | 34/57 59.6% (46.7%,71.4%) | 47/51 92.2% (81.5%,96.9%) | 44/47 93.6% (82.8%,97.8%) | 9/97 9.3% (5.0%,16.7%) | 35/89 39.3% (29.8%,49.7%) | 44/78 56.4% (45.4%,66.9%) | 34/56 60.7% (47.6%,72.4%) | 47/50 94.0% (83.8%,97.9%) | 44/46 95.7% (85.5%,98.8%) | 9/77 11.7% (6.3%,20.7%) | 35/69 50.7% (39.2%,62.2%) | 44/59 74.6% (62.2%,83.9%) |
| DPIPP 2 | 58/62 93.5% (84.6%,97.5%) | 59/60 98.3% (91.1%,99.9%) | 43/43 100.0% (91.8%,100.0) | 17/34 50.0% (34.1%,65.9%) | 23/34 67.6% (50.8%,80.9%) | 25/32 78.1% (61.2%,89.0%) | 58/62 93.5% (84.6%,97.5%) | 59/60 98.3% (91.1%,99.9%) | 43/43 100.0% (91.8%,100.0%) | 17/34 50.0% (34.1%,65.9%) | 23/34 67.6% (50.8%,80.9%) | 25/32 78.1% (61.2%,89.0%) |
| DPIPP 4 | 55/58 94.8% (85.9%,98.2%) | 53/54 98.1% (90.2%,99.9%) | 39/40 97.5% (87.1%,99.9%) | 16/21 76.2% (54.9%,89.4%) | 15/20 75.0% (53.1%,88.8%) | 13/15 86.7% (62.1%,96.3%) | 55/58 94.8% (85.9%,98.2%) | 53/54 98.1% (90.2%,99.9%) | 39/40 97.5% (87.1%,99.9%) | 16/21 76.2% (54.9%,89.4%) | 15/20 75.0% (53.1%,88.8%) | 13/15 86.7% (62.1%,96.3%) |
| DPIPP 6 | 27/34 79.4% (63.2%,89.7%) | 26/33 78.8% (62.2%,89.3%) | 22/27 81.5% (63.3%,91.8%) | 20/28 71.4% (52.9%,84.7%) | 21/27 77.8% (59.2%,89.4%) | 16/18 88.9% (67.2%,96.9%) | 27/34 79.4% (63.2%,89.7%) | 26/33 78.8% (62.2%,89.3%) | 22/27 81.5% (63.3%,91.8%) | 20/28 71.4% (52.9%,84.7%) | 21/27 77.8% (59.2%,89.4%) | 16/18 88.9% (67.2%,96.9%) |
| DPIPP 8 | 12/17 70.6% (46.9%,86.7%) | 12/17 70.6% (46.9%,86.7%) | 7/11 63.6% (35.4%,84.8%) | 13/23 56.5% (36.8%,74.4%) | 13/22 59.1% (38.7%,76.7%) | 4/11 36.4% (15.2%,64.6%) | 12/17 70.6% (46.9%,86.7%) | 12/17 70.6% (46.9%,86.7%) | 7/11 63.6% (35.4%,84.8%) | 13/23 56.5% (36.8%,74.4%) | 13/22 59.1% (38.7%,76.7%) | 4/11 36.4% (15.2%,64.6%) |
| DPIPP 10 | 4/9 44.4% (18.9%,73.3%) | 3/7 42.9% (15.8%,75.0%) | | 5/9 55.6% (26.7%,81.1%) | 5/8 62.5% (30.6%,86.3%) | | 4/9 44.4% (18.9%,73.3%) | 3/7 42.9% (15.8%,75.0%) | | 5/9 55.6% (26.7%,81.1%) | 5/8 62.5% (30.6%,86.3%) | |
| DPIPP 0-6 | 174/211 82.5% (76.8%,87.0%) | 185/198 93.4% (89.1%,96.1%) | 148/157 94.3% (89.5%,97.0%) | 62/180 34.4% (27.9%,41.6%) | 94/170 55.3% (47.8%,62.6%) | 98/143 68.5% (60.5%,75.6%) | 174/210 82.9% (77.2%,87.4%) | 185/197 93.9% (89.7%,96.5%) | 148/156 94.9% (90.2%,97.4%) | 62/160 38.8% (31.5%,46.5%) | 94/150 62.7% (54.7%,70.0%) | 98/124 79.0% (71.0%,85.3%) |
| DPIPP 8-10 | 16/26 61.5% (42.5%,77.6%) | 15/24 62.5% (42.7%,78.8%) | 22/27 81.5% (63.3%,91.8%) | 18/32 56.2% (39.3%,71.8%) | 18/30 60.0% (42.3%,75.4%) | 16/18 88.9% (67.2%,96.9%) | 16/26 61.5% (42.5%,77.6%) | 15/24 62.5% (42.7%,78.8%) | 7/11 63.6% (35.4%,84.8%) | 18/32 56.2% (39.3%,71.8%) | 18/30 60.0% (42.3%,75.4%) | 4/11 36.4% (15.2%,64.6%) |